0001193125-26-207549
SEC filingTScan Therapeutics reported Q1 2026 revenue of $1.0 million and a net loss of $28.7 million, with R&D expenses down $7.9 million year-over-year; cash and equivalents stood at $128.1 million as of March 31, 2026, sufficient to fund operations into the second half of 2027.
TScan Therapeutics’ Q1 2026 financial results reflect strategic prioritization and operational discipline: revenue declined year-over-year due to timing shifts in Amgen collaboration activities, not underlying program setbacks. The $7.9 million reduction in R&D expenses—driven by supply purchase timing and deliberate focus on the heme franchise—was the primary driver behind the $5.4 million improvement in net loss. Management explicitly tied this expense discipline to advancing TSC-101 toward Phase 3, reinforcing capital allocation rigor. Gross margin is not disclosed, as the company remains pre-revenue with no product sales; all revenue is collaboration-based and non-recurring. The $128.1 million cash position—down $24.4 million from December 31, 2025—supports runway into H2 2027, aligning with near-term clinical catalysts: early data from ALLOHA Cohort C and launch of the pivotal Phase 3 trial for TSC-101 in Q2 2026. Notably, the press release highlights robust enrollment in Cohort C using the commercial-ready manufacturing process, signaling de-risking of scale-up. While forward-looking statements mention upcoming milestones—including Phase 1 initiation for TSC-102-A01/A03 and preclinical autoimmunity data in H2 2026—no quantitative financial guidance was provided. The absence of EPS or revenue guidance, combined with the reliance on partnership revenue, underscores continued execution risk ahead of potential inflection points later this year.